ResMed (RMD) Expected to Announce Earnings on Wednesday

ResMed (NYSE:RMD - Get Free Report) is expected to be announcing its earnings results after the market closes on Wednesday, April 23rd. Analysts expect the company to announce earnings of $2.37 per share and revenue of $1.28 billion for the quarter. Parties that wish to register for the company's conference call can do so using this link.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Trading Up 0.7 %

RMD stock traded up $1.40 during midday trading on Friday, hitting $212.89. 1,109,562 shares of the company's stock were exchanged, compared to its average volume of 1,024,057. ResMed has a one year low of $176.92 and a one year high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $31.27 billion, a PE ratio of 25.13, a price-to-earnings-growth ratio of 1.53 and a beta of 0.75. The stock's fifty day moving average price is $223.12 and its 200-day moving average price is $234.52.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.00%. The ex-dividend date was Thursday, February 13th. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Insider Activity

In other news, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the transaction, the insider now owns 9,725 shares in the company, valued at approximately $2,289,265. The trade was a 48.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $209.85, for a total value of $1,680,688.65. Following the transaction, the chief executive officer now owns 455,472 shares of the company's stock, valued at $95,580,799.20. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,013 shares of company stock valued at $11,298,816. 0.71% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Mizuho set a $265.00 price target on shares of ResMed in a research note on Wednesday. The Goldman Sachs Group began coverage on ResMed in a report on Thursday, January 16th. They set a "buy" rating for the company. Stifel Nicolaus cut their price target on ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a report on Wednesday, March 5th. Piper Sandler lifted their target price on ResMed from $252.00 to $260.00 and gave the company a "neutral" rating in a research report on Friday, January 31st. Finally, JPMorgan Chase & Co. upped their price target on ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, ResMed presently has a consensus rating of "Moderate Buy" and an average price target of $251.00.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.